Aug 20, 2025 • GlobeNewswire
NEUTRAL
HUTCHMED Completes Patient Enrollment of SANOVO Phase III Trial of ORPATHYS® and TAGRISSO® Combination as a First-Line Therapy for Certain Lung Cancer Patients in China
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Aug. 20, 2025 ( GLOBE NEWSWIRE ) -- HUTCHMED ( China ) Limited ( "HUTCHMED" ) ( Nasdaq/AIM:HCM. HKEX:13 ) today announces the completion of patient enrollment of SANOVO, a China Phase III study of ORPATHYS® ( savolitinib ) and TAGRISSO® ( osimertinib ...
Aug 19, 2025 • Zacks Commentary
SOMEWHAT-BULLISH
Best Momentum Stock to Buy for August 19th
CENX, MC and HCM made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on August 19, 2025.
Aug 07, 2025 • Benzinga
SOMEWHAT-BULLISH
HUTCHMED Reports 2025 Interim Results - HUTCHMED ( China ) ( NASDAQ:HCM )
- Indications expansion driving growth and ATTC platform enriching pipeline - - $455 million in net income attributable to HUTCHMED driven by non-core partial disposal - HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Aug. 07, 2025 ( GLOBE NEWSWIRE ) -- HUTCHMED ( China ) Limited ( "HUTCHMED", ...
Jul 25, 2025 • Benzinga
SOMEWHAT-BULLISH
Inmagene Biopharmaceuticals Announces Completion of Merger with Ikena Oncology and Concurrent Private Placement of $75 Million - Ikena Oncology ( NASDAQ:IKNA )
The combined company will operate under the name "ImageneBio, Inc." and will begin trading on Nasdaq under the ticker symbol "IMA" at market open on Monday, July 28, 2025
Jul 25, 2025 • GlobeNewswire
SOMEWHAT-BULLISH
Inmagene Biopharmaceuticals Announces Completion of Merger with Ikena Oncology and Concurrent Private Placement of $75 Million
The combined company will operate under the name "ImageneBio, Inc." and will begin trading on Nasdaq under the ticker symbol "IMA" at market open on Monday, July ...
Jul 15, 2025 • GlobeNewswire
NEUTRAL
Ikena Oncology Announces Stockholder Approval of Merger with Inmagene Biopharmaceuticals
Combined Company to Trade on Nasdaq Under Ticker "IMA" ...